An  	An  	 DT	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
safety  	safety  	 NN	O
data  	data  	 NNS	O
of  	of  	 IN	O
repeat  	repeat  	 NN	B-NP
administrations  	administrations  	 NNS	I-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A-ABO  	A-ABO  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
A  	A  	 DT	O
new  	new  	 JJ	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
( 	( 	 -LRB-	O
BoNTA-ABO 	BoNTA-ABO 	 NNP	B-NP
;  	;  	 :	O
Dysport  	Dysport  	 NNP	B-NP
[ 	[ 	 -LRB-	O
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	B-NP
] 	] 	 -RRB-	O
;  	;  	 :	O
Medicis  	Medicis  	 NNP	B-NP
Aesthetics 	Aesthetics 	 NNP	I-NP
,  	,  	 ,	O
Scottsdale 	Scottsdale 	 NNP	B-NP
,  	,  	 ,	O
AZ 	AZ 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
recently  	recently  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	O
and  	and  	 CC	O
Drug  	Drug  	 NNP	B-NP
Administration  	Administration  	 NNP	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
To  	To  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
safety  	safety  	 NN	O
of  	of  	 IN	O
repeat  	repeat  	 NN	B-NP
administrations  	administrations  	 NNS	I-NP
of  	of  	 IN	I-NP
BoNTA-ABO  	BoNTA-ABO  	 JJ	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
variable  	variable  	 JJ	O
dosing 	dosing 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
report  	report  	 NN	O
summarizes  	summarizes  	 VBD	O
an  	an  	 DT	O
interim  	interim  	 JJ	O
analysis  	analysis  	 NN	O
that  	that  	 WDT	O
does  	does  	 VBZ	O
not  	not  	 RB	O
address  	address  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 JJ	B-NP
profile 	profile 	 NN	I-NP
.  	.  	 .	O
Over  	Over  	 IN	O
24  	24  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
1415  	1415  	 CD	O
subjects  	subjects  	 NNS	B-NP
underwent  	underwent  	 VBD	O
open-label  	open-label  	 JJ	B-NP
retreatment  	retreatment  	 NN	I-NP
with  	with  	 IN	O
BoNTA-ABO 	BoNTA-ABO 	 JJ	B-NP
.  	.  	 .	O
Patients  	Patients  	 NNS	O
were  	were  	 VBD	O
retreated  	retreated  	 VBN	O
with  	with  	 IN	O
50  	50  	 CD	O
units  	units  	 NNS	O
or  	or  	 CC	O
a  	a  	 DT	O
variable  	variable  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
50 	50 	 CD	O
,  	,  	 ,	O
60 	60 	 CD	O
,  	,  	 ,	O
70 	70 	 CD	O
,  	,  	 ,	O
or  	or  	 CC	O
80  	80  	 CD	O
units  	units  	 NNS	O
based  	based  	 VBN	O
on  	on  	 IN	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
muscle  	muscle  	 NN	B-NP
mass 	mass 	 NN	I-NP
.  	.  	 .	O
Dose  	Dose  	 NNP	O
was  	was  	 VBD	O
divided  	divided  	 VBN	O
among  	among  	 IN	O
five  	five  	 CD	O
points  	points  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
glabellar  	glabellar  	 JJ	B-NP
region 	region 	 NN	I-NP
.  	.  	 .	O
Retreatments  	Retreatments  	 NNP	B-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
if  	if  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
85  	85  	 CD	O
days  	days  	 NNS	O
had  	had  	 VBD	O
elapsed  	elapsed  	 VBN	O
between  	between  	 IN	O
treatments  	treatments  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
glabellar  	glabellar  	 JJ	B-NP
line  	line  	 NN	I-NP
severity  	severity  	 NN	I-NP
score  	score  	 NN	I-NP
was  	was  	 VBD	O
reassessed  	reassessed  	 VBN	O
as  	as  	 IN	O
moderate  	moderate  	 JJ	O
or  	or  	 CC	O
severe 	severe 	 JJ	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
were  	were  	 VBD	O
followed  	followed  	 VBN	O
up  	up  	 RP	O
at  	at  	 IN	O
seven 	seven 	 CD	O
,  	,  	 ,	O
14 	14 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
30  	30  	 CD	O
days  	days  	 NNS	O
postinjection 	postinjection 	 NN	B-NP
,  	,  	 ,	O
then  	then  	 RB	O
monthly 	monthly 	 JJ	O
.  	.  	 .	O
Endpoints  	Endpoints  	 NNP	B-NP
were  	were  	 VBD	O
adverse  	adverse  	 JJ	B-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
AE 	AE 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Of  	Of  	 IN	O
1415  	1415  	 CD	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
932  	932  	 CD	O
( 	( 	 -LRB-	O
66 	66 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
experienced  	experienced  	 VBN	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
AE 	AE 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
rate  	rate  	 NN	O
of  	of  	 IN	O
treatment-emergent  	treatment-emergent  	 NNP	B-NP
AE  	AE  	 NNP	O
( 	( 	 -LRB-	O
TEAE 	TEAE 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
in  	in  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
fixed-  	fixed-  	 JJ	O
and  	and  	 CC	O
variable-dose  	variable-dose  	 JJ	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
Most  	Most  	 JJS	B-NP
TEAE  	TEAE  	 NNP	I-NP
were  	were  	 VBD	O
rated  	rated  	 VBN	O
mild  	mild  	 JJ	O
( 	( 	 -LRB-	O
70 	70 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
moderate  	moderate  	 JJ	O
( 	( 	 -LRB-	O
20 	20 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
majority  	majority  	 NN	O
( 	( 	 -LRB-	O
87 	87 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
3361 	3361 	 CD	O
/ 	/ 	 CD	O
3861 	3861 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
all  	all  	 DT	O
TEAE  	TEAE  	 NNP	B-NP
instances  	instances  	 NNS	I-NP
were  	were  	 VBD	O
considered  	considered  	 VBN	O
not  	not  	 RB	O
related  	related  	 VBN	O
or  	or  	 CC	O
unlikely  	unlikely  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
related  	related  	 VBN	O
to  	to  	 TO	O
study  	study  	 VB	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
overall  	overall  	 JJ	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
TEAE  	TEAE  	 NNP	B-NP
and  	and  	 CC	O
related  	related  	 JJ	O
events  	events  	 NNS	O
remained  	remained  	 VBD	O
relatively  	relatively  	 RB	O
constant  	constant  	 JJ	O
or  	or  	 CC	O
decreased  	decreased  	 VBD	O
over  	over  	 IN	O
repeat  	repeat  	 NN	B-NP
cycles 	cycles 	 NNS	I-NP
.  	.  	 .	O
Multiple  	Multiple  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
with  	with  	 IN	O
fixed  	fixed  	 JJ	O
or  	or  	 CC	O
variable  	variable  	 JJ	O
dosing  	dosing  	 NN	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNS	B-NP
are  	are  	 VBP	O
well  	well  	 RB	O
tolerated 	tolerated 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
cumulative  	cumulative  	 JJ	B-NP
safety  	safety  	 NN	I-NP
issues  	issues  	 NNS	I-NP
because  	because  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
AE  	AE  	 NNP	B-NP
remained  	remained  	 VBD	O
relatively  	relatively  	 RB	O
constant  	constant  	 JJ	O
or  	or  	 CC	O
decreased  	decreased  	 VBD	O
over  	over  	 IN	O
repeated  	repeated  	 JJ	O
treatment  	treatment  	 NN	B-NP
cycles 	cycles 	 NNS	I-NP
.  	.  	 .	O
